Ignite Plasma Presents Research

Ignite Plasma Presents Research COST ACTION PLASTHER FINAL MEETING 17/06/2025

Research Objectives

To address this challenge, the research focuses on identifying the RONS that can penetrate biological barriers and determining the physical parameters able to modulate them. The team is working to optimize factors such as gas flow rate and electric field intensity using a conventional double ring-electrodes plasma jet supplied with helium at 1 L/min and applying nanopulse high-voltage parameters of 0-10 kV, 0-30 kHz, and 10%.

Moving Forward

This presentation at the Plaster Cost Action meeting represents another step in Ignite Plasma’s research into plasma-based cancer therapies. The collaboration with Laboratory of Plasma Physics, Sorbonne University and Inserm, Centre de Recherche Saint-Antoine in Paris continues to advance our understanding in this field of medical research.

For more information about Ignite Plasma’s research initiatives and partnerships, please contact us or Follow us: #IgnitePlasma

Jun 17 – 20 2025 Barcelona, Spain

Ignite Plasma participated in the Plaster Cost Action meeting in June 2025, where our consortium partner Sorbonne University represented our research in cold atmospheric plasma therapy.

Emerick Biaffeu, a team member from Sorbonne University’s Laboratory of Plasma Physics in France, presented his team’s research on behalf of Ignite Plasma, focusing on the therapeutic potential of cold atmospheric plasma (CAP) for treating challenging cancer types.

Research Focus

The presentation outlined CAP as a promising therapeutic approach for patients suffering from cholangiocarcinoma (CCA – cancer of the biliary tract) and pancreatic ductal adenocarcinoma (PDAC) inducing selective cytotoxic effects. These effects can be mediated by different properties of CAP, e.g. reactive oxygen and nitrogen species (RONS) and electric field.

The research has shown CAP’s anti tumor efficacy through tumor growth regression in murine models carrying subcutaneous tumors. However, the team recognizes that in patient situations, epithelial tissue may influence the penetration of plasma-generated species, potentially reducing treatment efficacy.

Poster A Plaster COST Action Meeting